INTERVENTIONALPROTOCOL REGISTERED2021-000103-20
An explorative randomized, placebo-controlled and double-blind intervention crossover study: Transvamix (100mg/mL THC / 50mg/mL CBD) to treat chronic pain in Epidermolysis Bullosa
Genetic Epidermolysis Bullosa
Locally preserved from EU Clinical Trials Register (EudraCT)Open EU Clinical Trials Register (EudraCT)↗last source update not reported
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- Not reported
- Enrollment
- Not reported
- Start date
- 2021-07-15
- Sponsor
- University Medical Center Groningen
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
Genetic Epidermolysis BullosaGenetic Epidermolysis Bullosa
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
No structured eligibility criteria were reported.
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- cc0e0ec1-e945-4fa2-a0a5-0edc0469ac9e
- Retrieved
- 14/09/2026, 12:09:19
- SHA-256
- fc606c0c2ec5eabf05e0a4eb98e3d8a6614242bb0b7397f23e10b2d10d007da9